Ambev S.A. share price today

Ambev S.A.'s share price was $2.77 at the close on 4 November 2026. It has been moving sideways for 2 weeks. That is 8.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $3, and at that close it sat 39% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Ambev S.A. is in stage 1. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 2 weeks running.

Over the last 10 years the share price moved −53% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Ambev S.A. declared BRL 0.27 per local share for Dec 2025, and BRL 1.11 over the last four reported quarters. It reports in Brazilian reais, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield.

Ambev S.A. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Ambev S.A. earned BRL 3.4 B of net profit in the Jun 2026 quarter, +24.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was BRL 15.5 B. Over 4 years profit has grown 5.2% a year on average. That is 16.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned BRL 2.7 B.

For the full year, FY25 profit was BRL 15.5 B (+7.4% on the year before).

Why profit moved: revenue changed +0.3% on a year earlier and the margin moved +1.8 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +13.2% and revenue −3.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

This company reports in Brazilian reais, not US dollars, so the money charts are left out here. The figures in the text are in that currency (BRL); nothing is converted.

Ambev S.A. reported BRL 20.1 B of revenue in the Jun 2026 quarter, +0.3% on the same quarter a year earlier. Over 4 years it has grown 4.9% a year on average. The last full year, FY25, came in at BRL 88.2 B. The last four reported quarters add to BRL 88.3 B.

Revenue is everything the company billed its customers in the period.

FY25 revenue was BRL 88.2 B, −1.4% on the year before.

Recent pace: the last four quarters grew −3.4% on average, against 4.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −3.8%, against +4.6% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +10.1%, against +6.2% a year (accelerating).

This company reports in Brazilian reais, not US dollars, so the money charts are left out here. The figures in the text are in that currency (BRL); nothing is converted.

Ambev S.A.'s operating margin was 23.7% in the Jun 2026 quarter, 1.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 22.1% and 25.5%. The latest quarter is within that range.

Operating margin is what is left from every BRL 100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 22.1% and 25.5%, and FY25's 25.5% is the highest of them.

Why the margin moved: operating margin changed +1.8 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 169% of Ambev S.A.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in BRL 24.5 B of operating cash against BRL 15.5 B of profit. After BRL 4.6 B of spending on assets, BRL 19.9 B was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

This company reports in Brazilian reais, not US dollars, so the money charts are left out here. The figures in the text are in that currency (BRL); nothing is converted.

Ambev S.A. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent BRL 15.3 B on assets over the last 3 years. Averaged over those years that is 5.8% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: BRL 15.3 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

This company reports in Brazilian reais, not US dollars, so the money charts are left out here. The figures in the text are in that currency (BRL); nothing is converted.

Ambev S.A.'s P/E is 14.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Ambev S.A.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 22.7%; each line tells part of the story. This is based on 12 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Ambev S.A. earned a ROE of 18% in FY25. That is up from a low of 15% in FY24. Its return on capital used (ROIC) is 19.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 17.6% net margin and 0.61× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 17.6% net margin × 0.61× asset turnover × 1.63× leverage (assets divided by equity) ≈ 17.5% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 25.3% − 6.2% = +19.1 percentage points. The 6.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

Ambev S.A. has total debt of BRL 2.9 B against shareholder equity of BRL 88.9 B as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.04 in FY21 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

This company reports in Brazilian reais, not US dollars, so the money charts are left out here. The figures in the text are in that currency (BRL); nothing is converted.

We have no ownership or short-position figures for Ambev S.A., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 3.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Ambev S.A., the Z-score is 4.61. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.61 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Ambev S.A. is not among the largest members shown in this industry comparison for Beverages - Brewers.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Ambev S.A. is the 2nd largest of 7 Beverages - Brewers companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Anheuser-Busch InBev SA/NV. Just below it: Fomento Económico Mexicano, S.A.B. de C.V., Constellation Brands, Inc., Molson Coors Beverage Company, The Boston Beer Company, Inc. and Compañía Cervecerías Unidas S.A.

Beverages - Brewers companies close in size

1. Anheuser-Busch InBev SA/NV $166.6 billion
2. Ambev S.A. $42.9 billion
3. Fomento Económico Mexicano, S.A.B. de C.V. $39.6 billion
4. Constellation Brands, Inc. $24.6 billion
5. Molson Coors Beverage Company $8 billion
6. The Boston Beer Company, Inc. $2.3 billion
7. Compañía Cervecerías Unidas S.A. $2 billion

All 7 Beverages - Brewers companies, largest first

Companies close in size in other industries

356. Prudential Financial, Inc. $43.5 billion · Insurance - Life
357. IQVIA Holdings Inc. $43.5 billion · Diagnostics & Research
358. Ambev S.A. $42.9 billion
359. BeOne Medicines AG $42.8 billion · Biotechnology
360. Revolution Medicines, Inc. $42.7 billion · Biotechnology

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.